- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/16 - Anti-Parkinson drugs
Patent holdings for IPC class A61P 25/16
Total number of patents in this class: 5023
10-year publication summary
|
154
|
173
|
224
|
370
|
465
|
392
|
441
|
456
|
402
|
123
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7958 |
70 |
| Takeda Pharmaceutical Company Limited | 2961 |
67 |
| H. Lundbeck A/S | 1252 |
45 |
| AstraZeneca AB | 3042 |
38 |
| Hoffmann-La Roche Inc. | 3060 |
36 |
| Janssen Pharmaceutica N.V. | 3839 |
35 |
| Sumitomo Pharma Co., Ltd. | 626 |
35 |
| The Regents of the University of California | 18943 |
32 |
| Taisho Pharmaceutical Co., Ltd. | 844 |
31 |
| Novartis AG | 11238 |
28 |
| Genentech, Inc. | 3742 |
27 |
| Sumitomo Dainippon Pharma Co., Ltd. | 226 |
27 |
| BIAL - Portela & CA, S.A. | 243 |
25 |
| Merck Sharp & Dohme LLC | 3689 |
25 |
| Bristol-myers Squibb Company | 5080 |
24 |
| Pfizer Inc. | 3322 |
23 |
| Merck Sharp & Dohme Corp. | 2247 |
22 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 762 |
22 |
| Eisai R&D Management Co., Ltd. | 1304 |
22 |
| Centre National de La Recherche Scientifique | 9632 |
21 |
| Other owners | 4368 |